6?-ethylchenodeoxycholic acid (6-ECDCA), OCA, INT-747 ( DrugBank: 6-ECDCA )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
93原発性胆汁性胆管炎1

93. 原発性胆汁性胆管炎


臨床試験数 : 298 薬物数 : 252 - (DrugBank : 59) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 115
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-005012-42-ES
(EUCTR)
18/12/201530/10/2015A Phase 3b clinical trial to measure the effect of Obeticholic acid against a placebo, in conjunction with standard treatment, on selected clinical measurements in patients with the liver disease, Primary Biliary Cirrhosis.A Phase 3b, Double Blind, Randomized, Placebo Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cirrhosis Primary Biliary Cirrhosis
MedDRA version: 18.1;Level: LLT;Classification code 10036680;Term: Primary biliary cirrhosis;System Organ Class: 100000004871;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: Obeticholic acid
Product Code: OCA, INT-747
INN or Proposed INN: Obeticholic Acid
Other descriptive name: 6?-ethylchenodeoxycholic acid (6-ECDCA), OCA, INT-747
Product Name: Obeticholic acid
Product Code: OCA, INT-747
INN or Proposed INN: Obeticholic Acid
Other descriptive name: 6?-ethylchenodeoxycholic acid (6-ECDCA), OCA, Int-747
Intercept Pharmaceuticals Inc.NULLNot RecruitingFemale: yes
Male: yes
350Phase 3Portugal;United States;Serbia;Estonia;Spain;Chile;Israel;Italy;Switzerland;France;Denmark;Australia;Netherlands;Korea, Republic of;Finland;Turkey;Lithuania;Austria;United Kingdom;Hungary;Mexico;Canada;Argentina;Belgium;Poland;Bulgaria;Germany;New Zealand;Sweden